Antibody-Drug Conjugate Kills Neuroblastoma Cells.
Researchers have developed an antibody-drug conjugate with the potential to treat neuroblastoma. The agent targets ALK, which is found on neuroblastoma cells but not healthy cells, delivering a drug that causes DNA cross-links. Researchers have found that the antibody-drug conjugate kills ALK-expressing cells in vitro and increases survival in mouse models of neuroblastoma.